Skip to main content
OpenTrials
Completed

NCT Number: NCT06306066

Coronary Thermo-dilution Derived Flow-indices in Chronic Coronary Syndrome

Patients scheduled for elective coronary angiography due to chronic coronary syndrome are recruited at admission to hospital before the coronary anatomy is known. Immediately after coronary angiography measures thermo-dilution derived flow indices are obtained in the left left anterior descending artery (LAD). The patients are followed through telephone-calls and medical records at 1 and 2 years after inclusion and at completion of the study. The hypothesis is that elevated index of microcirculatory resistance (IMR),(>25) is associated with all-cause death, myocardial infarction (MI) and hospitalization due to congestive heart failure (CHF).

The primary analysis is the relationship between IMR and the composite outcome all-cause death, MI and hospitalization due to CHF.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Danderyd University Hospital and Karolinska Institutet Danderyds University Hospital (KI DS)

Stockholm, 182 88, Sweden

About this study

Patients scheduled for elective coronary angiography due to chronic coronary syndrome are recruited at admission to hospital after written informed consent has been obtained and before the coronary anatomy is known. Blood sampling is performed from the arterial sheath before coronary angiography. The coronary angiography is done according to clinical practice. Immediately after coronary angiography measures thermo-dilution derived flow indices are obtained in the LAD (methods below). Interventions of epicardial lesions are then performed at the percutaneous coronary intervention (PCI)-operators discretion.

Fractional Flow Reserve (FFR), Coronary Flow Reserve(CFR) and IMR measurements

All indices FFR, CFR and IMR are measured in the left anterior descending artery (LAD). The flow measurements shall be obtained before PCI in the LAD. Further assessment of flow in LAD after PCI are optional. Flow measurements in the right coronary artery and circumflex lesions are optional.

Flow measurements:

A coronary guidewire with pressure and temperature sensors (PressurewireX, Abbott Inc, Calif., USA) is advanced in the LAD. The thermistor is placed > 70 mm from the catheter-tip and three millilitres of cold saline is injected into the LAD three times through the guiding catheter and thermo-dilution resting curves in triplicate are obtained. The patient then receives an intravenous infusion of adenosine (167 µg/kg/min) during approximately two minutes to induce stable hyperaemia. Again, three millilitres of cold saline is injected into the LAD through the guiding catheter and hyperaemic thermos-dilution curves in triplicate are obtained.

FFR is calculated as the ratio of distal coronary pressure (Pd) to proximal coronary pressure (Pa) at hyperaemia. CFR will be calculated through as the ratio of mean transit time of resting thermo-dilution curves (Tmnbas) divided by mean transit time of hyperaemic thermos-dilution curves (Tmnhyp). IMR is calculated as the product of Pd and Tmnhyp during stable hyperaemia. If FFR is <0.75 IMR can be overestimated and will be calculated differently (Yong et al.); Corrected index of microcirculatory resistance (IMRcorr) = Pa x Tmnhyp x ([1.35 x Pd/Pa] - 0.32).

Recordings of systolic blood pressure, diastolic blood pressure, Tmnbas, Tmnhyp, Pa, Pd, IMR, CFR will be saved and analysed off-line by a dedicated physician.

Follow-up The patients are followed through telephone-calls and medical records at 1 and 2 years and after inclusion and at completion of the study December 2022.

Patients with extensive atherosclerotic disease in the left main or the LAD with risk of complications when advancing a pressure wire making flow-measures not possible will be followed according to the protocol but excluded from the primary analysis. Patients with chronic total occlusions (CTO) in the LAD making flow-measures impossible in the LAD will be followed according to the protocol but excluded from the primary analysis.

Survival analysis The null hypothesis is that subjects with IMR >25 have the same outcome (death, MI, and hospitalization due to CHF) as subjects with IMR≤25. Assumptions are that 30% of subjects have IMR >25, the hazard ratio is 2.0, the event rate is 0.09 per year, censoring rate 0.3/year, average follow-up 3 years. With 395 subjects the power is 80% to reject the null hypothesis. α=0.05.

Biomarkers in relation to IMR Post-hoc power calculation; the null hypothesis is that no variables are associated with IMR. Assumptions; effect-size (R2) = 0.20; maximum variables in the regression analysis = 15; α = 0.05. With a power of 0.80 a sample size of 89 subjects are needed to reject the null hypothesis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with stable angina pectoris or suspected angina pectoris who are scheduled for coronary angiography
  • Age 18 years - 85 years
  • Life expectancy >2 years

Exclusion criteria

  • Acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI] and unstable angina pectoris)
  • Known CHF
  • Prior heart transplantation
  • Prior coronary artery by-pass grafting
  • Hypertrophic cardiomyopathy (Septum >15 mm)
  • Valvular disease
  • Not eligible for coronary angiogram
  • Cancer within three years of admission
  • Peri-myocarditis
  • Atrial fibrillation with heart beats per minute >120
  • Asthma

Treatment and study plan

Primary outcomes

  1. Rate of all-cause mortality, MI and/or hospitalization due to CHF

    Time frame: Study completion, approximately 5 years

    Cumulative rate of all-cause mortality, MI and/or hospitalization due to CHF at study completion

Secondary outcomes

  1. Rate of all-cause mortality

    Time frame: Study completion, approximately 5 years

    Cumulative rate of all-cause at study completion

  2. Rate of hospitalization due to CHF.

    Time frame: Study completion, approximately 5 years

    Cumulative rate of hospitalization due to CHF at study completion

  3. Rate of all-cause mortality and/or MI

    Time frame: Study completion, approximately 5 years

    Cumulative rate of all-cause mortality and MI at study completion

  4. Rate of MI

    Time frame: Study completion, approximately 5 years

    Cumulative rate of MI at study completion

  5. Rate of stroke

    Time frame: Study completion, approximately 5 years

    Cumulative rate of Stroke at study completion

  6. Rate of ischemic stroke

    Time frame: Study completion, approximately 5 years

    Cumulative rate of Ischemic stroke at study completion

  7. Rate of unscheduled revascularization

    Time frame: Study completion, approximately 5 years

    Cumulative rate of Unscheduled revascularization at study completion

Sponsors and collaborators

Lead sponsor

Karolinska Institutet

Other

Collaborators

  • Abbott

Registry information

Official study title

Coronary Microvascular Dysfunction in Chronic Coronary Syndrome - Invasive Assessment With Thermo-dilution Technique in the LAD and Biobanking in an All-comer Population

Important dates

Study start
2015
Primary completion
2021
Study completion
2022
First posted
Mar 12, 2024
Registry last updated
Mar 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.